CoChat

Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%. Objective: To investigate the views of individuals with IPF and pulmonologists on the diagnosis and management of IPF to understand treatment patterns. Methods: Interviews and/or online surveys were completed by patients and pulmonologists from Canada, France, Germany, Italy, Spain, and the UK. Responses from physicians were analyzed by time between diagnosis and treatment initiation in the majority of patients with IPF (group A, > 4 months; group B, ≤4 months). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant. Results: The physicians in group A saw fewer patients, were less comfortable discussing the IPF prognosis with patients, and had less belief in the benefits of antifibrotic treatments than the physicians in group B. These physicians’ attitudes contrasted with those of the patients, who wanted more information about the IPF prognosis and pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects. Differences between countries were found regarding physicians’ comfort in discussing the prognosis at diagnosis and access to care. Conclusions: Several barriers to antifibrotic treatment, principally reflecting the differing views and values of patients and physicians, were identified in this study, suggesting a need for better patient-physician communication about pharmacological therapy for IPF.

Overview

Integrity signals

Registry

Crossref · 10.1159/000490667

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Cited by

See all 69

Metadata

Authors
Maher, T. M., Swigris, J. J., Kreuter, M., Wijsenbeek, M., Cassidy, N., Ireland, L., Axmann, J., & Nathan, S. D.
Affiliations
  • Royal Brompton Hospital (GB)
  • National Jewish Health (US)
  • Heidelberg University (DE)
  • Erasmus MC (NL)
  • F. Hoffmann-La Roche AG (CH)
  • Inova Fairfax Hospital (US)
Venue
Respiration
Publisher
S. Karger AG
Published
2018
Volume
96
Issue
6
Pages
514-524
ISSN
  • 0025-7931 (ISSN-L)
  • 1423-0356
OpenAlex
W2885464317
Cited by
69
References
22
Citations by year
2026: 2 · 2025: 3 · 2024: 9 · 2023: 11 · 2022: 12 · 2021: 8 · 2020: 15 · 2019: 8 · 2018: 1
FWCI
6.02
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Respiration (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • GlaxoSmithKline
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative Care and End-of-Life Issues
Keywords
idiopathic pulmonary fibrosis, antifibrotic therapy, barriers to treatment, patient-physician communication, physician attitudes, prognosis disclosure, treatment initiation timing, patient expectations, health care access, disease progression prevention, adverse drug reactions
MeSH terms
Pulmonologists, Adult, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Surveys and Questionnaires, Idiopathic Pulmonary Fibrosis, Watchful Waiting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.